广东东阳光科技控股股份有限公司 董事会薪酬与考核委员会关于公司 2025 年员工持股计划相 关事项的核查意见 广东东阳光科技控股股份有限公司（以下简称"公司"）董事会薪酬与考核 委员会根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《关于上市公司实施员工持股计划试点的指 导意见》(以下简称"《指导意见》")、《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》(以下简称"《规范运作》")等相关法律、法规、规范性文 件及《公司章程》的有关规定，在认真审阅薪酬与考核委员会 2025 年第二次会 议相关会议资料的基础上，经充分、全面的讨论与分析，依据相关规定，就公司 2025 年员工持股计划相关事项发表核查意见如下： 三、公司实施员工持股计划有利于建立和完善劳动者与所有者的利益共享机 制，使员工利益与公司长远发展更紧密地结合，有利于进一步提升公司治理水平， 提高员工的凝聚力和公司竞争力，充分调动员工积极性和创造性，实现企业的长 远可持续发展。 综上，公司第十二届董事会薪酬与考核委员会同意实施 2025 年员工持股计 划，并同意将 2025 年员 ...

广东东阳光科技控股股份有限公司 2025 年半年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、业绩预告的具体适用情形：实现盈利，且净利润与上年同期相比上升 50% 以上； | 证券代码：600673 | 证券简称：东阳光 | | 编号：临 2025-46 号 | | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 东科 | 01 | | 2、预计公司 2025 年半年度实现归属于上市公司股东的净利润 58,300.00 万元到 66,300.00 万元,同比增长比例 157.48%-192.81%；预计实现归属于上市 公司股东的扣除非经常性损益的净利润 47,100.00 万元到 55,100.00 万元，同比 增长比例 159.73%-203.84%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 1、经财务部门初步测算，预计公司 2025 年半年度实现归属于上市 ...

| 债券代码：242444 | 债券简称：25 | 东科 | | | | | --- | --- | --- | --- | --- | --- | | | | | 01 | | | | | | | | 编号：临 | | | | | | | | 2025-45 | | 证券代码：600673 | 证券简称：东阳光 | | | | 号 | 广东东阳光科技控股股份有限公司 关于参与参股公司吸收合并暨关联交易的公告 广东东阳光科技控股股份有限公司（以下简称"公司"）参股公司宜昌东 阳光长江药业股份有限公司（以下简称"长江药业"）与公司关联方广东东阳光 药业股份有限公司（以下简称"东阳光药"或"要约人"）签署了《吸收合并协 议》，由东阳光药向长江药业换股股东发行 H 股股份并注销换股股东持有的长江 药业 H 股（以下简称"换股 H 股"）的方式吸收合并长江药业（以下简称"合并 换股事项"或"本次换股"）。公司作为东阳光药、长江药业的参股股东将参与本 次合并换股事项，公司所持有的长江药业 21,815,200 股 H 股股份预计可换得 5,750,792 股东阳光药发行的 H 股股份（最终换股数量以实际交易情况为准，以 ...

广东东阳光科技控股股份有限公司 2025 年员工持股计划管理办法 广东东阳光科技控股股份有限公司 2025 年员工持股计划管理办法 为了规范广东东阳光科技控股股份有限公司 2025 年员工持股计划（以下简称 "本员工持股计划"或"本持股计划"）的实施，确保公司发展战略和经营目标的 实现，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《关于上市公司实施员工持股计划试点 的指导意见》（以下简称"《指导意见》"）《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》（以下简称"《自律监管指引第 1 号》"）等有关法律、行 政法规、规章、规范性文件和《公司章程》的规定和公司实际情况，公司制定了《广 东东阳光科技控股股份有限公司 2025 年员工持股计划管理办法》（以下简称"本管 理办法"）。 第一条 本员工持股计划的目的 本员工持股计划的目的为充分调动公司员工对公司的责任意识，吸引和保留优 秀管理人才和核心骨干员工，增强员工的积极性、主动性、创造性和凝聚力，激发 公司的发展潜力，从而确保公司发展战略的实现，促进公司长期、持续、健康发展。 第二条 ...

广东东阳光科技控股股份有限公司 2025 年员工持股计划（草案） 证券简称：东阳光 证券代码：600673 债券简称：25 东科 01 债券代码：242444 广东东阳光科技控股股份有限公司 2025 年员工持股计划摘要（草案） 二〇二五年七月 1 广东东阳光科技控股股份有限公司 2025 年员工持股计划（草案） 声明 本公司及全体董事保证本员工持股计划及其摘要不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2 广东东阳光科技控股股份有限公司 2025 年员工持股计划（草案） 风险提示 一、广东东阳光科技控股股份有限公司 2025 年员工持股计划须经公司股东 会批准后方可实施，本员工持股计划能否获得公司股东会批准，存在不确定性； 二、本员工持股计划的具体参与人数、资金规模、股票规模、认购情况等要 素存在不确定性； 三、本员工持股计划的业绩考核具有一定的可实现性，但未来由于受到宏观 经济环境的变化、行业景气度的波动、市场竞争加剧等原因的影响，也可能存在 业绩无法达成的风险。本员工持股计划设定的业绩考核指标仅为方案设计合理预 测使用，不代表公司对未来的盈利预测，不构 ...

广东东阳光科技控股股份有限公司 独立董事：覃继伟 第十二届董事会独立董事专门会议 第四次会议决议 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司独立董 事管理办法》（以下简称"《管理办法》"）《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》（以下简称"《规范运作》"）及《广东东阳光科技控股股 份有限公司章程》（以下简称"《公司章程》"）的有关规定，广东东阳光科技控股 股份有限公司（以下简称"公司"）全体独立董事于 2025 年 7 月 10 日以通讯方 式召开第十二届董事会独立董事专门会议第四次会议。应参会独立董事 3 人，实 际参会独立董事 3 人，会议的召集、召开及表决程序符合《公司法》《管理办法》 《规范运作》的有关规定，所做决议合法有效。经与会独立董事审议，一致通过 了如下决议： 一、审议通过了《关于参与参股公司吸收合并暨关联交易的议案》 本次合并换股事项系基于公司对参股公司上市进程的配合与支持，有利于实 现公司分享参股公司上市的潜在收益。本次交易遵循自愿、公平合理、协商一致 的原则，不存在向关联方输送利益的情形，不存在损害公司及中小股东利益的情 形。因此我们一致同意 ...

Group 1 - The PVDF concept sector experienced a decline of 1.65%, ranking among the top declines in concept sectors, with major declines seen in companies like Sanmei Co., Ltd., Juhua Co., Ltd., and Shenzhen New Star [1][2] - Among the PVDF concept stocks, only two stocks saw price increases, with Jinming Precision Machinery rising by 1.46% and ST Lianchuang by 0.59% [1][2] - The main capital outflow from the PVDF concept sector today was 297 million yuan, with 12 stocks experiencing net outflows, and six stocks seeing outflows exceeding 10 million yuan [2][3] Group 2 - Juhua Co., Ltd. had the highest net capital outflow of 123.45 million yuan, followed by Dongyangguang with 99.37 million yuan and Putailai with 22.80 million yuan [2][3] - The stocks with the highest net capital inflow included Haohua Technology, Jinming Precision Machinery, and Sanmei Co., Ltd., with inflows of 23.99 million yuan, 5.89 million yuan, and 3.76 million yuan respectively [2][3] - The trading volume for Juhua Co., Ltd. was 2.10%, while the trading volume for Jinming Precision Machinery was 4.04% [3]

Group 1 - The core patent of Dongyangguang Pharmaceutical's invention "Bridge cyclic compound as a hepatitis C inhibitor and its preparation method" has won the second Hubei Patent Gold Award, highlighting the company's innovation and core competitiveness in new drug development [1][5][12] - The hepatitis C virus (HCV) infection rate in China is approximately 10 million, with new reported cases around 200,000 per year, indicating a significant public health challenge due to low diagnosis and treatment rates [6][7] - Dongyangguang Pharmaceutical established its research goal in 2010 to develop hepatitis C drugs tailored for the Chinese market, aiming to provide effective treatment options for the large patient population [6][7] Group 2 - The drug, Phosphoric acid imetavine, was developed over ten years and became the first domestically developed hepatitis C NS5A inhibitor in China, receiving approval in 2020 [7][8] - Phosphoric acid imetavine has a high overall cure rate of 99.8% when used in combination with Sofosbuvir, and it was included in the national medical insurance directory in December 2021, significantly reducing the cost for patients [7][8] - The patent strategy for Phosphoric acid imetavine includes a comprehensive layout that began in 2013 and has expanded to cover various aspects of the drug, enhancing its market competitiveness and protecting its innovations [10][11] Group 3 - Since its establishment in 2001, Dongyangguang Pharmaceutical has focused on R&D, applying for over 2,400 invention patents and holding more than 1,400 authorized patents, making it a leader in patent filings among domestic pharmaceutical companies [12] - The company has built a complete innovation chain from basic research to clinical transformation, with 150 approved drugs globally and over 100 in development, including nearly 50 first-class innovative drugs [12] - Dongyangguang Pharmaceutical aims to continue driving development through innovation, enhancing its core competitiveness, and contributing to the high-quality development of the pharmaceutical industry [12]

| 证券代码：600673 | 证券简称：东阳光 | | 编号：临 | 2025-42 号 | | --- | --- | --- | --- | --- | | 债券代码：242444 | 债券简称：25 | 东科 01 | | | 广东东阳光科技控股股份有限公司 关于控股股东之一致行动人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 本次质押股份不存在被用作重大资产重组业绩补偿等事项的担保或者其他 保障用途。 二、股东累计质押股份情况 截至本公告披露日，深圳东阳光实业及其一致行动人累计质押股份情况如下： | | | | | | | | | 已质押股份情况 | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 持股数量 | 持股比 | 本次质押前 | 本次质押后 | 占其所 持股份 | 占公司 总股本 | 已质押 | 已质押 | 未质押 | 未质押 | | 股东名称 | （ ...

Group 1: Chemical Industry Overview - The construction project growth rate in the basic chemical sector has turned negative, indicating a potential turning point for the industry [1] - The fixed asset growth rate is a leading indicator for supply growth, and the current negative trend in construction projects suggests that the chemical sector is approaching a new upward cycle [1][10] - The overall chemical sector requires multiple factors to resonate for the next upward cycle to begin, with oil prices being a key pricing anchor for most chemical products [1] Group 2: AI for Science (AI4S) in Chemical R&D - AI for Science represents a new paradigm in materials science research, with the potential to grow into a trillion-dollar market, significantly enhancing research efficiency through literature learning, AI model calculations, and automated laboratories [2] - The application of AI4S in the pharmaceutical sector is accelerating, with successful models for drug discovery and solid-state research being established [2] - China is positioned to lead in the AI4S market due to its comprehensive chemical manufacturing industry and supply chain, with key companies like 泰控股 and 志特新材 emerging as leaders [2][46] Group 3: Investment Opportunities in New Industries - The AI hardware sector, particularly in light connections, power supplies, and liquid cooling, presents significant investment opportunities, with companies like 东阳光 recommended for attention [3] - The solid-state battery market is expected to undergo transformation driven by demand from emerging sectors, with large-scale commercialization anticipated from 2026 onwards [3] - The robotics sector, particularly with tendon-driven systems, is gaining traction, with significant market potential as the technology matures [3][50] Group 4: Supply and Demand Dynamics - The supply side of the chemical industry is currently in a downward trend, with construction project growth rates at historically low levels [9][10] - Demand for chemical products has been affected by various external factors, including trade tensions and geopolitical events, but the overall demand is stabilizing as tariff disturbances recede [13] - The global chemical product sales accounted for 45% of the total market, indicating a strong position in the global supply chain [13] Group 5: Oil Market Impact - The oil market is facing increasing supply pressures, with predictions of excess supply in 2025, leading to a potential decline in oil prices [17][20] - Geopolitical tensions, particularly in the Middle East, continue to create uncertainty in oil prices, which directly impacts the profitability of the chemical sector [28][32] - The OPEC+ group is expected to increase production, further exacerbating the supply-demand imbalance in the oil market [25]